Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Roche’s Tecentriq approved by NICE for Cancer Drugs Fund inclusion

Roche’s Tecentriq approved by NICE for Cancer Drugs Fund inclusion

2nd November 2017

Roche has announced that the UK's National Institute for Health and Care Excellence (NICE) has recommended its drug Tecentriq for use within the Cancer Drugs Fund.

Final draft guidelines from the UK regulator has backed the atezolizumab therapy for use in patients whose urothelial cancer has not yet been treated, and who receive cisplatin-based chemotherapy.

NICE previously ruled that Tecentriq was not a cost-effective option for people who had already received chemotherapy, although its benefits for those who had not previously been treated were acknowledged.

Roche was therefore invited to submit a Cancer Drugs Fund proposal to demonstrate the drug's plausible potential for cost effectiveness, allowing the company to address the regulator's uncertainties and show how Tecentriq's clinical benefits are enough to balance its cost.

Richard Erwin, general manager of Roche in the UK, said: "We welcome the news that patients will now be able to access atezolizumab via the Cancer Drugs Fund. This demonstrates the importance of working collaboratively and flexibly with NICE and NHS England."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.

We currently have 8 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.